Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


July 28, 2015 6:22 AM ET

Biotechnology

Company Overview of Protiva Biotherapeutics Inc.

Company Overview

Protiva Biotherapeutics Inc., a development stage biotechnology company, develops nucleic acid based pharmaceutical products. The company focuses on developing products to fight various human diseases, such as cancer, influenza, Ebola, inflammatory diseases, and chronic viral infections. Its products include Pro 1, a tumor cell growth inhibitor, which kills tumor cells and inhibits tumor growth; Pro-101, an siRNA product that acts to inhibit the production of a protein involved in tumor growth; Pro-B, which acts to inhibit the expression of a protein, apolipoprotein B; Pro-EBOV and Pro-MARV that act to inhibit the replication of the Ebola and Marburg viruses; and Stable Nucleic-Acid Lipid Pa...

100-3480 Gilmore Way

Burnaby, BC V5G 4W7

Canada

Founded in 2000

26 Employees

Phone:

604-630-5061

Fax:

604-630-5103

Key Executives for Protiva Biotherapeutics Inc.

Chief Financial Officer
Chief Scientific Officer and Executive Vice President
Age: 51
Compensation as of Fiscal Year 2015.

Protiva Biotherapeutics Inc. Key Developments

Dicerna Pharmaceuticals, Inc. Enters into License Agreement and Development and Supply Agreement with Protiva Biotherapeutics Inc. and Tekmira Pharmaceuticals Corporation

On November 16, 2014 Dicerna Pharmaceuticals, Inc., a Delaware corporation (Dicarna), entered into a License Agreement and a Development and Supply Agreement with Protiva Biotherapeutics Inc. (Protiva) and Tekmira Pharmaceuticals Corporation (Tekmira). Under the terms of the License Agreement, Protiva and Tekmira grant Dicerna an exclusive (except with respect to previously granted license rights), worldwide license to use Protiva and Tekmira's proprietary lipid nanoparticle (LNP) technology for delivery of certain therapeutics to treat primary hyperoxaluria type 1 (PH1). During the term of the License Agreement, Dicerna will not in-license from a third party for use with a licensed product a drug delivery system competitive with Protiva's LNP technology, provided, however, that if Dicerna in-licenses such a delivery system from a third party after the first commercial sale of a licensed product, the license grant of the LNP technology to Dicerna will thereafter be on a non-exclusive basis. Dicerna made an upfront payment of $2,500,000 in connection with the signing of the License Agreement. Dicerna will make potential total development and approval milestone payments of $22,000,000. Dicerna is also required to pay a mid-single digit percentage royalty on all net sales of licensed products during the royalty period. The royalty period in a country is the longer of the expiration of the data exclusivity granted by the country's regulatory authority, the last to expire of certain patent claims applicable to products sold in such country, and the 10 year anniversary of the commencement of commercial sales in such country. The License Agreement may be terminated if: either party commits a material, uncured breach, Dicerna does not use commercially reasonable efforts to develop or commercialize the licensed product, Dicerna commences an action challenging the validity of the licensed patents; or if either party initiates bankruptcy, liquidation or similar proceedings. Contemporaneously with the execution of the License Agreement, Dicerna, Protiva and Tekmira entered into the Development and Supply Agreement. Under the terms of the Development and Supply Agreement, Protiva will perform certain development and other services for Dicerna and manufacture and test licensed products for Dicerna, including: the manufacture of all licensed products for pre-clinical testing and development, design of the final licensed product formulation to be used as the clinical development candidate, manufacture of the final formulated licensed product for clinical trials, assistance in the preparation of regulatory submissions and interactions with the FDA and its foreign equivalents, and performing technical transfer to Dicerna's selected contract manufacturer for the licensed product. Dicerna will pay Protiva on a time and materials basis at an agreed upon FTE rate and with an administrative mark-up on the acquisition of materials. The Development and Supply Agreement provides that intellectual property developed by a single party pursuant to activities contemplated by the agreement and not based on the practice of certain confidential information or intellectual property of the other party or directed solely to the other party's materials provided pursuant to the agreement shall be owned by such party. The agreement provides for joint ownership of certain jointly developed intellectual property as well as joint or collaborative prosecution, maintenance, and defense of such intellectual property.

Similar Private Companies By Industry

Company Name Region
BioLipids Inc. Americas
Medicago Inc. Americas
Glyko Biomedical Ltd. Americas
PerkinElmer BioSignal, Inc. Americas
Genome Prairie Inc. Americas

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Protiva Biotherapeutics Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.